| Téléchargement | - Voir la version finale : Foot-and-mouth disease: optimization, reproducibility, and scalability of high-yield production of virus-like particles for a next-generation vaccine (PDF, 1.2 Mio)
- Voir les données supplémentaires : Foot-and-mouth disease: optimization, reproducibility, and scalability of high-yield production of virus-like particles for a next-generation vaccine (JPG, 622 Kio)
|
|---|
| DOI | Trouver le DOI : https://doi.org/10.3389/fvets.2020.00601 |
|---|
| Auteur | Rechercher : Mignaqui, Ana Clara1; Rechercher : Ferella, Alejandra; Rechercher : Cass, Brian1; Rechercher : Mukankurayija, Larissa1; Rechercher : L'Abbé, Denis1; Rechercher : Bisson, Louis1; Rechercher : Sánchez, Cintia; Rechercher : Scian, Romina; Rechercher : Cardillo, Sabrina Beatriz; Rechercher : Durocher, Yves1; Rechercher : Wigdorovitz, Andrés |
|---|
| Affiliation | - Conseil national de recherches du Canada. Thérapeutique en santé humaine
|
|---|
| Format | Texte, Article |
|---|
| Sujet | FMDV; VLPs; mammalian cells; transient gene expression; emergency vaccine |
|---|
| Résumé | Inactivated Foot-and-Mouth Disease (FMD) vaccine has proven to be effective in the control of the disease. However, its production has some disadvantages, including the costly biosafety facilities required for the production of huge amounts of growing live virus, the need of an exhaustive purification process to eliminate non-structural proteins of the virus in the final formulations in order to differentiate infected from vaccinated animals and variable local regulatory restrictions to produce and commercialize the vaccine. Thus, a novel vaccine against FMD that overcome these restrictions is desirable. Although many developments have been made in this regard, most of them failed in terms of efficacy or when considering their transferability to the industry. We have previously reported the use of transient gene expression in mammalian cells to produce FMD virus-like particles (VLPs) as a novel vaccine for FMD and demonstrated the immunogenicity of the recombinant structures in animal models. Here, we report the optimization of the production system by assaying different DNA:polyethylenimine concentrations, cell densities, and direct and indirect protocols of transfection. Also, we evaluated the reproducibility and scalability of the technology to produce high yields of recombinant VLPs in a cost-effective and scalable system compatible with industrial tech-transfer of an effective and safe vaccine. |
|---|
| Date de publication | 2020-09-23 |
|---|
| Maison d’édition | Frontiers Media |
|---|
| Licence | |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | 40f6aef2-4c13-4077-970f-0bbc5ebc7dac |
|---|
| Enregistrement créé | 2021-04-30 |
|---|
| Enregistrement modifié | 2021-05-04 |
|---|
